Single oral dose study of two isosorbide-based aspirin prodrugs in the dog

John F. Gilmer, Michael A. Murphy, Jean A. Shannon, Colm G. Breen, Sheila A. Ryder and John M. Clancy

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland
E-mail: gimerjf@tcd.ie

Note: This is the pre-peer-reviewed version of the following article:
which has been published in final form on the publisher's website. Direct links to the definitive publisher-authenticated version:
http://dx.doi.org/10.1211/0022357022007

Abstract

The objective of this study was to compare two aspirin prodrugs, isosorbide diaspirinate (ISDA) and a nitroaspirin (ISMNA), with aspirin in terms of effects on dog platelet function after administration of a single oral dose. Groups of six dogs were administered ISDA (2 mg kg⁻¹), ISMNA (4 mg kg⁻¹) or aspirin (2 mg kg⁻¹). Blood was sampled at 1, 2, 4, 8, 12 and 24 h post-dosing and evaluated for capacity to generate post-clotting thromboxane (TX)B₂. The aggregation response to arachidonic acid (AA) (100 μM), ADP (30 μM) or collagen (10 μg mL⁻¹) was estimated at each time-point using the whole blood impedance method. Plasma ISMN following oral administration of ISMNA was also measured and compared with plasma ISMN following administration of a physical mixture of ISMN and aspirin. ISD administration (2 mg kg⁻¹) was associated with a significant reduction (P < 0.05) in serum TXB₂ at 12 and 24 h (>90%) post-dosing and persistent inhibition of AA-induced platelet aggregation. ISDA administration caused a more marked depression of post-clotting TXB₂ levels than aspirin in this study, although its ability to inhibit platelet aggregation was less consistent than that of aspirin. The nitroaspirin ISMNA was least effective at inhibiting platelet aggregation response or TXB₂ production. The ISMN AUC₀-2₄h for the ISMNA-treated dogs was 77% of that for the physical mix-treated dogs and the tₘₐₓ was delayed. This study indicates that the two aspirin esters cause aspirin-like effects on platelet function, probably through aspirin release, when administered orally to dogs.

Introduction

Aspirin is effective in the treatment and prevention of a variety of cardiovascular and cerebrovascular diseases (Patrono 1994). Regular aspirin use is also associated with a significant reduction in the risk of certain types of cancer (Giovannucci 1999; Gardiner & Gilmer 2003). Other findings point to a possible inverse relationship between aspirin and risk of Alzheimer’s disease and other forms of dementia (Zandi et al. 2002). However, aspirin use carries a significantly increased risk of gastrointestinal (GI) bleeding, which is evident at doses as low as 10 mg day⁻¹ (Kurata & Abbey 1990; Cryer et al. 1995). This effect appears to be due to a complex interplay of factors that are not fully understood. However, local suppression of cyclooxygenase (COX)-1-dependent gastro-protective functions and topical toxicity due to ion trapping are recognised as especially important contributors to aspirin toxicity (Rainsford 1989; Hawkey 1996). Pharmaceutical strategies, such as buffering or enteric coating, do not significantly reduce the risk of side effects (Kelly et al. 1996).

One potentially useful approach to this problem lies in the design of aspirin prodrugs that liberate aspirin after absorption from the GI tract (Jones 1985). There are several reasons to expect that such compounds would have significantly diminished gastric toxicity. Esterification, by masking the carboxylic acid group, would obviate the topical irritancy component of aspirin GI toxicity, which is associated with the aspirin carboxylic acid group. Moreover, the prodrug form would not possess intrinsic COX-1 inhibitory properties, and would therefore not inhibit COX-1 until hydrolysis post-absorption. This hypothesis has not been properly tested with a true aspirin prodrug. However, available NSAID ester prodrugs generally possess lower gastric toxicity than their parent compounds (Tammara et al. 1994; Mahfouz et al. 1999; Bonina et al. 2002).

Another reason for the interest in aspirin prodrugs is that esters of aspirin generally exhibit higher aqueous stability than aspirin itself (Nielsen & Bungaard 1989) because esterification masks the carboxylate, which performs an autocatalytic role in aspirin hydrolysis (St Pierre & Jencks 1968). Several reports concerning the design of aspirin prodrugs are directed at forms of the drug that are suitable for percutaneous absorption due to their higher stability and lipophilicity (e.g. Loftsson et al. 1981).
A parallel mutual prodrug strategy involves the design of nitro-aspirins in which aspirin is linked via an ester to a nitric oxide donor (Minuz et al. 1998; Del Soldato et al. 1999). Nitric oxide possesses gastro-protective properties through its ability to promote mucosal blood flow and suppress leucocyte adhesion. The prototype compound in this class, NCX-4016, exhibits greater gastric tolerability than aspirin in several animal models (Takeuchi et al. 1998; Tashima et al. 2000). NCX-4016 is now in phase II clinical trials (http://www.nicox.com/pages/keyprods.html#ncx4016).

A major obstacle to the development of aspirin prodrugs has been that aspirin esters undergo hydrolysis to salicylate esters in blood, and ultimately salicylic acid, rather than aspirin (Nielsen & Bungaard 1989). Aspirin ester prodrugs, therefore, can be more appropriately described as salicylic acid prodrugs. We have recently reported two aspirin derivatives of isosorbide that markedly depart from this general pattern because of an unusually rapid and specific butyrylcholinesterase [EC 3.1.1.8] mediated hydrolysis. One of these, ISMN (Figure 1), the aspirin ester of isosorbide mononitrate (ISMN), is exclusively hydrolysed to aspirin in rabbit plasma and is a more potent inhibitor of platelet aggregation to arachidonic acid (AA) in rabbit platelet-rich plasma (PRP) than aspirin (Gilmer et al. 2001). The diastirinate analogue of ISMN, isosorbide diastirinate (ISDA), which lacks a nitrate group, is an unusually efficient aspirin prodrug in human plasma (Gilmer et al. 2002).

Figure 1 Chemical structures of aspirin (1), ISMNA (2) and ISDA (3).

The aim of the present study was to evaluate the efficiency of these prodrugs in vivo by measuring their effect on dog platelet function relative to aspirin, following a single low oral dose (aspirin equivalent of 2 mg kg$^{-1}$). The extent of absorption of ISMN following administration of ISMNA relative to an equimolar dose of ISMN was estimated by using ISMN as a plasma marker in a second group of dogs.

Materials and Methods

Animal treatment

General procedures for animal care and housing were in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Animal Resources, Commission on Life Sciences 1996) and the requirements of the Animal Welfare Act (7USC 2131, 1985). The pharmacokinetic study was performed at the Bioresources Unit, Trinity College Dublin, which is a Department of Health approved facility under the 1876 Cruelty to Animals Act as amended by Council Directive 86/609 and SI 17/1994, and it conforms to the standards required by Annex 2 of the directive. Dogs were housed individually in stainless steel cages. None of the dogs used in this study had exposure to salicylates in the previous 14 days. No adverse effects were observed during the course of the study.

Anti-platelet dosing study design

Six healthy adult beagle dogs were used in each treatment group, three male and three female. ISDA (2 mg kg$^{-1}$), ISMNA (4 mg kg$^{-1}$) and aspirin (2 mg kg$^{-1}$) were administered orally by capsule. The ISDA dosage was approximately 75% of the aspirin dose on a molar basis, while the ISMNA dosage was approximately the same as the aspirin dose on a molar basis. Individual doses were based on animal weight, which was between 9.0 and 11 kg on the day of treatment.

Ex vivo platelet aggregation samples

Baseline blood samples were collected for aggregation analysis 1-4 weeks before dosing. One blood sample (approximately 2.5 mL) per dog was collected three times within a day, at least 2 h apart, into sodium citrate tubes. One blood sample per dog was obtained immediately prior to dosing (time zero) and at approximately 1, 2, 4, 8, 12 and 24 h into sodium citrate tubes (approximately 3.5%). All blood samples were stored at room temperature and aggregation analysis was performed as soon as possible after collection. Samples were also obtained for platelet count: One blood sample per dog (approximately 1 mL) was collected at the first baseline time-point and at the 12 h and 24 h time-points into tubes containing EDTA for the determination of the platelet count. The platelet counts were measured on a Technicon H.1
Thromboxane blood samples

One blood sample per dog (3 mL) was collected at the baseline time-point into tubes containing no anticoagulant. On the day of the study one blood sample per dog was obtained at 0 min (immediately prior to dosing) and at approximately 1, 2, 4, 8, 12 and 24 h post-dosing into tubes containing no anticoagulant. The tubes were placed into a bath maintained at 37°C and allowed to clot for 1 h to obtain maximal thromboxane (TXB)2 formation. The samples were then removed and indomethacin (0.1 mM final concentration) added to deter further COX activity. The samples were centrifuged at 4°C and the serum separated and frozen until analysis.

TXB2 analysis

To remove interfering components each serum sample was extracted using octadecyl (C-18) reversed-phase columns before the ELISA assay for TXB2. The extraction efficiency was measured by spiking serum samples with approximately 5000 cpm of 3H-TXB2 (Amersham Life Sciences) before extraction and counting the extracted sample for recovery of radiolabelled TXB2. All solvent was evaporated under a stream of nitrogen at 37°C. Tubes were capped and stored at -20°C until assay. Samples were assayed for TXB2 using commercial competitive ELISA kits (Neogen Co.).

Aggregometry

Whole blood aggregation (impedance method) was monitored using a ChronoLog 540CS Aggregometer. The citrated blood samples were diluted 1:1 with modified Tyrode’s buffer (Grauer et al. 1992) (0.137 M NaCl, 0.0027 M KCl, 0.0056 M CaCl2, 0.0021 M MgCl2, 0.0027 M K2HPO4, 0.012 M NaHCO3, 2 IU mL-1 preservative free heparin, pH 7.40, sterile filtered). Aggregation analysis was performed within 3 h of sample collection. Final concentrations of ADP, AA, high-dose collagen and low-dose collagen used to induce platelet aggregation were, respectively, 30 μM, 100 μM, 10 μg mL-1 and 1 μg mL-1. All dogs used in the study responded to AA in the impedance experiment at baseline.

Plasma ISMN study

Two groups of two male, purpose-bred, Labrador-cross dogs (approximately 25 kg) were used. Group A was treated orally with ISMNA (4 mg kg-1) in acetone:propane-2-diol (35:65). Group B was treated orally with a physical mix of aspirin and ISMN (1:1, 4 mg kg-1) in acetone:propane-2-diol (35:65). Blood was sampled (approximately 10 mL) from the jugular vein at 0, 0.5, 1, 2, 4, 8, 12 and 24 h. No food was administered before the 12 h sample. Each blood sample was split between two tubes, one containing EDTA and the other containing heparin. The samples were centrifuged at 4250 rpm. Plasma was aspirated off and frozen at -80°C until analysis. Analysis for ISMN was performed using a fully validated gas chromatography method employing electron capture detection. A 500 μL plasma aliquot was treated with 50 μL of a solution of internal standard (750 mg/100 mL isosorbide-2-mononitrater in methanol). Tert-butyl-methyl-ether (1 mL) was added and the resulting mixture stirred at 10 rpm for 10 min followed by centrifugation at 3400 g for 10 min. A 2 μL aliquot of the organic layer was injected. No significant differences were observed between blood samples anticoagulated with EDTA or heparin.

Data treatment

Platelet aggregation, platelet count and TXB2 data were analysed by repeated measures or one-way ANOVA, or by the appropriate non-parametric measures (Friedman or Kruskal-Wallis tests). Multiple comparisons that showed significance (P < 0.05) were evaluated using Dunnett’s or Dunn’s test as appropriate. Plasma ISMN AUC0-24 h values were determined using the WinNonlin pharmacokinetic software package. Cmax and tmax values were obtained directly from the analytical data.

Results

TXB2 analysis

Normalised serum TXB2 levels, calculated as a percentage of the pre-treatment mean (baseline and time zero) for individual dogs in each of the treatment groups, are presented in Figure 2. Mean serum TXB2 levels for each treatment group are presented in Figure 3. Marked intra- and inter-individual variations in TXB2 concentration were observed in samples from the pre-treatment (baseline and time zero) time-points. For example, mean pre-treatment values in the ISDA group were 1117 ± 383 ng mL-1 (range 687-2490 ng mL-1). High intra- and inter-individual variations in canine serum and urinary TXB2 have been reported previously (Yamanaka et al. 1993). An increase in TXB2 production was observed in the ISDA treatment group at the 1 h time-point relative to the pre-treatment mean and a significant increase at the 2 h time-point (P < 0.05). This is probably due to normal biological variation; for example, there was no significant difference between the 2 h values and the baseline values. The mean pre-treatment (baseline and time zero) TXB2 level among all dogs in this study was 846 ± 513 ng mL-1. Dog serum TXB2 levels are the highest among common domestic animals (887 ± 123 ng mL-1); McKellar et al. (1999) reported previously (Yamanaka et al. 1993).
ISDA administration was associated with a reduction in mean serum TxB$_2$ levels at the 4, 8, 12 and 24 h time-points and a significant decrease at the 12 h ($P < 0.05$) and 24 h ($P < 0.01$) time-points relative to the respective pre-treatment mean. Mean concentrations at the 12 h and 24 h time-points were 241 ± 108 (range: 139-426) ng mL$^{-1}$ and 107 ± 99 (range: 29-290) ng mL$^{-1}$, respectively, corresponding to 21.6 and 9.6%, respectively, of the pre-treatment mean in these dogs. Serum TxB$_2$ levels in samples from three of six dogs at the 24 h time-point were <5% of the pre-treatment mean and all six dogs exhibited >80% inhibition of the respective pre-treatment mean. Mean serum TxB$_2$ levels at the 4 h and 8 h time-points were, respectively, 266 ± 92 (range: 131-376) ng mL$^{-1}$ and 367 ± 117.2 (range: 189-645) ng mL$^{-1}$, corresponding to 24 and 32.8% of the pre-treatment value, respectively. Statistically significant changes in mean post-clotting TxB$_2$ levels were not observed in the aspirin or ISMNA treatment groups. However, individual dogs in these groups exhibited >80% inhibition of TxB$_2$ relative to their respective pre-treatment mean at various time-points. ISMNA administration was generally associated with the least aspirin-like effect on TxB$_2$ synthetic capacity of the three drugs tested. Platelet count was 278 ± 69 ($\times 10^3$ mL$^{-1}$) at baseline, 266 ± 50.4 ($\times 10^3$ mL$^{-1}$) at 12 h and 267 ± 40.4 ($\times 10^3$ mL$^{-1}$) at 24 h. These variations were not considered to be biologically significant.

**Figure 2** Plots showing exogenously produced TxB$_2$ levels as a percentage of the respective pre-treatment mean TxB$_2$ (baseline and time zero) for dogs administered aspirin (2 mg kg$^{-1}$), ISDA (2 mg kg$^{-1}$) or ISMNA (4 mg kg$^{-1}$).

**Figure 3** Mean serum TxB$_2$ levels following oral administration of aspirin (■ 4 mg kg$^{-1}$), ISMNA (■ 4 mg kg$^{-1}$) or ISDA (□ 2 mg kg$^{-1}$) to adult beagles (s.d., n=6).

**Figure 4** Mean aggregation impedance (ohms) in response to arachidonic acid for dogs administered aspirin (■ 4 mg kg$^{-1}$), ISMNA (■ 4 mg kg$^{-1}$) or ISDA (□ 2 mg kg$^{-1}$) to adult beagles (s.d., n=6).
Platelet aggregation

Aggregation in whole blood was evaluated using the impedance method of Cardinal & Flower (1980). Mean aggregation amplitudes (ohms) in response to AA for dogs in each treatment group are presented in Figure 4. ISDA administration was associated with a significant decrease ($P < 0.05$) in mean aggregation amplitude in response to AA at the 8 h and 12 h time-points. Complete inhibition of AA-induced aggregation was observed in one, three, six, four and two of six dogs, respectively, at the 1, 2, 4, 8, 12 and 24 h time-points. Dogs in the aspirin treatment group also exhibited consistent inhibition of aggregation response to AA. Mean aggregation amplitudes for dogs in this group were 6, 0, 0, 0 and 0 ohms at 1, 2, 4, 8 and 12 h, respectively, whereas the pre-treatment mean was 13 ohms. Inhibition of aggregation response to AA was observed least consistently in the ISMNA treatment group. However, a statistically significant decrease in mean aggregation impedance was observed at the 8 h time-point with six of six dogs exhibiting complete or delayed aggregation response ($P < 0.05$). No abnormalities were observed in response to ADP (30 μM) or high-dose collagen (10 μg mL$^{-1}$) in any of the treatment groups; however, some incidence of delayed aggregation was observed in response to low-dose collagen (1 μg mL$^{-1}$) in the ISMNA and ISDA treatment groups (Figure 5). Samples from dogs in the aspirin treatment group were stimulated with collagen (1 μg mL$^{-1}$) at the 24 h time-point only. One of the samples did not aggregate; however data for the baseline response to low-dose collagen were not collected for dogs in this group. Aspirin is a weak inhibitor of collagen-induced platelet aggregation in all species as collagen-initiated aggregation can bypass the AA cascade. Aspirin is also a weak inhibitor of ADP aggregation and the results for the two prodrugs are, therefore, unsurprising.

Plasma ISMN results

Mean plasma ISMN levels following administration of either ISMNA or an ISMN-aspirin physical mix are presented in Figure 6 and parameters are given in Table 1. The ISMN AUC$_{0-24}$h for the ISMNA-treated dogs was 77% of that for the physical mix-treated dogs. ISMN shows complete oral bioavailability in humans (Major et al. 1984) but is reported to be somewhat less well absorbed in dogs (71.5%; Sponer et al. 1984). The analytical data indicates a $t_{max}$ for the ISMNA treatment group of 4 h whereas the physical mix $t_{max}$ was 2 h; however, there was no significant difference between ISMN levels at the 2 h time-point in the ISMNA treatment group (624 ng mL$^{-1}$) and the 4 h time-point (647 ng mL$^{-1}$).

Table 1 Pharmacokinetic parameters for ISMN in dogs (n=2) administered either a 1:1 physical mixture (4 mg kg$^{-1}$) of aspirin and ISMN, or ISMNA (4 mg kg$^{-1}$).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ISMNA</th>
<th>ISMN-aspirin mix</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC$_{0-24}$h (ng h mL$^{-1}$)</td>
<td>5662.75 (range 5517-6140)</td>
<td>7331.94 (range 6406-8850)</td>
</tr>
<tr>
<td>$C_{max}$ (ng mL$^{-1}$)</td>
<td>647 (range 639-656)</td>
<td>1175 (range 981-1370)</td>
</tr>
<tr>
<td>$t_{max}$ (h)</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

Figure 5 Mean whole blood impedance values (ohms) in response to low-level collagen (1 μg mL$^{-1}$) following administration of ISMNA (■ 4 mg kg$^{-1}$) or ISDA (□ 2 mg kg$^{-1}$) to beagles (n=6).

Figure 6 Mean ISMN plasma levels in dogs (n=2) administered either a 1:1 physical mixture of aspirin and ISMN (● - ) (4 mg kg$^{-1}$) or ISMNA (▲ - ) (4 mg kg$^{-1}$). The error bars mark the range of the two determinations.
Discussion

Thromboxane B₂ is the stable hydrolase of the highly evanescent TXA₂, one of the most potent platelet aggregatory and vasoconstrictive substances known. In this study ex vivo production of TXB₂ during clotting was used as a measure of functional platelet cyclooxygenase (COX-1) following oral administration of ISDA, ISMNA or aspirin. The post-clotting measurement of TXB₂ is the most frequently used means of evaluating COX inhibitors in humans and other species (McKellar et al. 1990; Patrigiani et al. 1994; Brideau et al. 1996) mainly because this approach reduces variability due to sampling, which profoundly affects direct measurement of TXA₂ and its metabolites.

Suppression of ex vivo TXB₂ production was most clearly observed in the ISDA treatment group with maximal mean inhibition (>90%) at the 24 h time-point. Inhibition of post cloting TXB₂ by ISDA at 24 h was greater than the maximal inhibition in the aspirin treatment group at 4 h (P < 0.05). ISDA administration was also associated with significant inhibition of platelet aggregation response to AA. Curiously, whereas aggregation amplitude correlated with diminished serum TXB₂ up to the 12 h time-point, thereafter these two indices of COX-1 activity diverged. Furthermore, for individual dogs in the ISDA treatment group there was no relationship between impedance response to AA, and post-clotting TXB₂ production at the 24 h time-point.

In the aspirin treatment group, blockade of the aggregation response to AA was maintained up to the 24 h time-point (Figure 5) whereas platelet capacity to generate TXA₂, as reflected in mean post-clotting TXB₂, had returned to normal (Figure 3).

Canine platelets have a short circulation lifespan and the return of biochemically competent cells within 24 h of administration of a single low dose of aspirin is expected (Oshima et al. 1984). In contrast, it appears that recovery of platelet function follows a similar time-course to that observed in humans (Rao et al. 1981). Canine platelets exhibit complex responses to AA and its metabolites with marked inter- and intra-breed differences in platelet sensitivity to TXA₂. There is little correlation between the ability of individual dogs to produce thromboxane and their aggregation response to AA, suggesting that inter-dog variability is due to the mechanism that mediates aggregation and secretion in response to TXA₂ (Johnson et al. 1979; McGoff et al. 1989). These variations are particularly apparent in the turbidometric aggregation model (Born 1962) using canine PRP (Chignard & Varagaitig 1976). Aggregation to AA in canine whole blood is usually less variable because of potentiation of the platelet response to AA by other mediators not present in PRP (Grauer et al. 1992; Kurata et al. 1995) but highly variable responses to AA have been reported (Jütten et al. 2000).

In this study, blood samples from all dogs at all baseline time-points responded normally to AA (10-14 ohms). In general, platelet aggregation response to AA and platelet capacity to generate TXA₂ correlated at the 4 h and 8 h time-points but not at the 12 h or 24 h time-points. These observations may be reflective of a complicated and possibly dynamic relationship between platelet sensitivity to thromboxane and thromboxane levels in the dog. Nevertheless, the strong inhibitory effects of ISDA on TXB₂ production as well as the general suppression of aggregatory response to AA in both prodrug treatment groups indicates that aspirin release occurs in vivo following oral administration of the two prodrugs.

One can only speculate on whether release occurred before or after absorption of the two prodrugs from the gut. The susceptibility of both compounds towards plasma-mediated hydrolysis (Gilmer et al. 2001, 2002) precludes the possibility of accurate direct plasma measurement of the intact species. However, several factors suggest that both prodrugs may be absorbed intact to some extent. ISMNA is stable towards aqueous hydrolysis and in the presence of α₂-chymotrypsin (t₁/₂ = 87 min), a typical digestive ‘esterase’, but is hydrolysed rapidly and with high specificity by serum cholinesterase (t₁/₂ = 2.8 min in 10% plasma; Gilmer et al. 2001). Moreover, aqueous and α₂-chymotrypsin-catalysed hydrolysis of both compounds occurs through the salicylate pathway, generating isosorbide derivatives and salicylic acid. These metabolites cannot account for the pharmacological effects of ISMNA and ISDA observed in this study. It is notable that ISMNA exhibited weaker anti-platelet effects than aspirin even though it is a more potent inhibitor of platelet aggregation in vitro. The preliminary pharmacokinetic study reported here suggests that the maximal systemic ISMN availability following ISMNA administration is delayed and less extensive than that following administration of an equimolar ISMN-aspirin mixture. Whether this is due to relatively poor absorption of ISMNA, poor dissolution or slow hydrolysis to ISMN is not clear. The lesser inhibitory effects of ISMNA on platelet function observed in this study, relative to aspirin or ISDA, appear to be due to limited absorption of the intact prodrug as aspirin release from ISMNA requires the presence of butyrylcholinesterase present principally in blood.

Conclusion

In this study two putative aspirin prodrugs were compared with aspirin as inhibitors of platelet function and platelet capacity to generate TXB₂ ex vivo in the dog. All three substances showed maximal effects on platelet aggregation at the 4 h time-point. Whereas aspirin inhibition of platelet function persisted to the 24 h time-point, aggregation impedance recovered in the two prodrug treatment groups. On the other hand, ISDA treatment had the most pronounced effect on ex vivo TXB₂ production, evident up to the 24 h time-point. The study indicates that these compounds are orally effective aspirin prodrugs. Both ISMNA and ISDA may be more suitable for percutaneous formulation than aspirin as they possess greater aqueous stability and are more lipophilic. Our current work is directed towards further probing of the absorption and stability characteristics of the two prodrugs and evaluating their gastric toxicity profile.
References


